R
52.98
-0.59 (-1.10%)
Previous Close | 53.57 |
Open | 53.58 |
Volume | 1,129,702 |
Avg. Volume (3M) | 571,430 |
Market Cap | 2,102,394,752 |
Price / Earnings (Forward) | 111.11 |
Price / Sales | 16.35 |
Price / Book | 7.39 |
52 Weeks Range | |
Earnings Date | 5 Aug 2024 |
Profit Margin | -31.93% |
Operating Margin (TTM) | -23.89% |
Diluted EPS (TTM) | -0.990 |
Quarterly Revenue Growth (YOY) | 67.60% |
Total Debt/Equity (MRQ) | 4.15% |
Current Ratio (MRQ) | 14.34 |
Operating Cash Flow (TTM) | -29.62 M |
Levered Free Cash Flow (TTM) | -19.18 M |
Return on Assets (TTM) | -10.58% |
Return on Equity (TTM) | -17.01% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Mixed |
Medical Devices (Global) | Mixed | Mixed | |
Stock | RxSight, Inc. | Bullish | Bullish |
Stockmoo Score
-0.7
Analyst Consensus | 3.0 |
Insider Activity | -4.0 |
Price Volatility | 2.0 |
Technical Moving Averages | -1.0 |
Technical Oscillators | -3.5 |
Average | -0.70 |
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Growth |
% Held by Insiders | 5.15% |
% Held by Institutions | 88.69% |
52 Weeks Range | ||
Price Target Range | ||
High | 72.00 (Jefferies, 35.90%) | Buy |
Median | 69.00 (30.24%) | |
Low | 66.00 (Needham, 24.58%) | Buy |
Average | 69.00 (30.24%) | |
Total | 2 Buy | |
Avg. Price @ Call | 53.56 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Jefferies | 29 Oct 2024 | 72.00 (35.90%) | Buy | 52.16 |
Needham | 13 Sep 2024 | 66.00 (24.58%) | Buy | 54.96 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
GOLDSHLEGER ILYA | - | 50.85 | -3,100 | -157,635 |
Aggregate Net Quantity | -3,100 | |||
Aggregate Net Value ($) | -157,635 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 50.85 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
GOLDSHLEGER ILYA | Officer | 07 Nov 2024 | Automatic sell (-) | 3,100 | 50.85 | 157,635 |
GOLDSHLEGER ILYA | Officer | 07 Nov 2024 | Option execute | 3,100 | - | - |
Date | Type | Details |
---|---|---|
07 Nov 2024 | Announcement | RxSight, Inc. Reports Third Quarter 2024 Financial Results |
24 Oct 2024 | Announcement | RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024 |
22 Aug 2024 | Announcement | RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |